Long QT Syndrome

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology (Ion Channel Dysfunction)
  4. Genetic Subtypes (LQTS 1, 2, 3)
  5. Acquired Long QT Syndrome
  6. QTc Measurement and Diagnosis
  7. Clinical Presentation and Torsades de Pointes
  8. Treatment: Beta-Blockers and Mexiletine
  9. ICD and High-Risk Management
  10. Drug Avoidance and Lifestyle
  11. Research Papers
  12. Connections
  13. Featured Videos

Back to Table of Contents

1. Overview

Long QT syndrome (LQTS) is a disorder of cardiac repolarization characterized by a prolonged QT interval on the electrocardiogram, predisposing affected individuals to a potentially life-threatening ventricular arrhythmia called torsades de pointes (TdP) — a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation and sudden cardiac arrest (SCA).

LQTS is divided into congenital (inherited ion channel mutations) and acquired (drug-induced or metabolic) forms:

The global burden of sudden cardiac death attributable to LQTS is substantial, with LQTS estimated to account for a significant proportion of sudden unexplained deaths in young individuals. Early diagnosis, risk stratification, and targeted therapy can dramatically reduce SCA risk.

Back to Table of Contents

2. Epidemiology

Congenital LQTS has an estimated prevalence of 1 in 2,000 individuals in the general population, making it one of the more common inherited primary arrhythmia syndromes. However, because many affected individuals remain asymptomatic for prolonged periods, the true prevalence may be higher.

LQTS is responsible for approximately 3,000–4,000 sudden deaths annually in the United States, most occurring in young individuals. SCA in apparently healthy young people (aged <40 years) is estimated to be caused by LQTS in 10–15% of cases. Swimming-triggered SCA in a child or young adult strongly suggests LQTS type 1; sudden death triggered by an alarm clock or doorbell in a young person suggests LQTS type 2.

Women with LQTS have longer QTc intervals than men at baseline (due to testosterone's shortening effect on QT) and face higher arrhythmia risk than men during adulthood, though boys have higher risk before puberty. Postpartum period (first 9 months after delivery) carries heightened SCA risk in LQTS type 2.

Back to Table of Contents

3. Pathophysiology (Ion Channel Dysfunction)

Cardiac repolarization depends on a precise balance between depolarizing inward currents (sodium — INa, calcium — ICaL) and repolarizing outward currents (potassium — IKr, IKs, IK1). The QT interval on the ECG represents the total duration of ventricular depolarization plus repolarization.

In LQTS, loss-of-function mutations in repolarizing potassium channels (LQTS 1, 2) or gain-of-function mutations in the depolarizing sodium channel (LQTS 3) tip this balance toward prolonged depolarization:

Prolonged repolarization generates early afterdepolarizations (EADs) — abnormal membrane potential oscillations during phases 2 and 3 of the action potential. EADs trigger premature beats that can initiate torsades de pointes.

Torsades de pointes literally means "twisting of the points" — the QRS complexes appear to rotate around the isoelectric baseline, reflecting changing ventricular activation directions. TdP typically self-terminates in 10–30 seconds (causing syncope/presyncope) but can degenerate into VF (causing SCA).

Back to Table of Contents

4. Genetic Subtypes (LQTS 1, 2, 3)

LQTS Type 1 (KCNQ1 gene, ~35% of genotyped cases):
Loss-of-function mutations in KCNQ1 reduce the slowly activating delayed rectifier potassium current (IKs). Characteristic trigger: exercise and swimming (sympathetic activation normally enhances IKs; without it, QT fails to shorten appropriately with rate increase). T-wave morphology: broad-based T waves in leads V4–V6. Beta-blockers are highly effective (>90% event reduction); the gene-specific trigger (swimming) warrants restriction from competitive aquatic sports.

LQTS Type 2 (KCNH2/hERG gene, ~30% of genotyped cases):
Loss-of-function mutations in KCNH2 reduce the rapidly activating delayed rectifier potassium current (IKr). hERG channel is particularly susceptible to drug block (structurally favorable for drug binding). Characteristic trigger: sudden auditory stimuli (alarm clocks, telephone, doorbell) due to reflex sympathetic activation superimposed on bradycardia. T-wave morphology: low-amplitude, notched T waves. Risk peaks postpartum. Beta-blockers moderately effective. Serum potassium augmentation (target K+ >4.5 mEq/L) and avoidance of IKr-blocking drugs critical.

LQTS Type 3 (SCN5A gene, ~10% of genotyped cases):
Gain-of-function mutations in SCN5A generate persistent late sodium current (INaL). Characteristic trigger: bradycardia during rest and sleep (late INa less tolerated at slow rates). ECG: late-onset peaked T waves (LQT3-type). Beta-blockers less effective (some patients may even worsen with beta-blockers at night due to worsening bradycardia). Mexiletine (sodium channel blocker, 200 mg three times daily) shortens QTc by blocking INaL; highly effective in LQTS3. Pacemaker implantation for severe bradycardia/pause-dependent TdP. High rate of SCA as first symptom.

Other subtypes:

Back to Table of Contents

5. Acquired Long QT Syndrome

Acquired LQTS is the most common form encountered clinically. Over 100 drugs can cause QT prolongation, primarily by blocking hERG/IKr channels:

Common offending drug classes:

Risk factors for acquired LQTS:

Back to Table of Contents

6. QTc Measurement and Diagnosis

The QT interval must be corrected for heart rate — QTc (corrected QT interval):

Normal QTc values:

Diagnostic criteria:

Genetic testing:

Back to Table of Contents

7. Clinical Presentation and Torsades de Pointes

The clinical spectrum ranges from completely asymptomatic (with incidental QT prolongation on ECG) to sudden cardiac death:

Asymptomatic: Approximately 30–40% of genotype-positive LQTS individuals remain event-free throughout life; risk varies with genotype, QTc value, and sex.

Syncope: The most common symptomatic presentation. TdP causes abrupt reduction in cardiac output leading to loss of consciousness within seconds. Episodes typically last 10–30 seconds then terminate spontaneously. Patients awaken confused and exhausted. Syncope during exertion (LQTS1) or in response to a sudden auditory stimulus (LQTS2) in a young person is a red flag.

Seizures: TdP-induced syncope may produce hypoxic convulsions, leading to misdiagnosis as epilepsy. LQTS should be considered in any young patient with unexplained "seizures" (particularly during exercise or emotionally charged situations) with normal interictal neurological examination.

Sudden cardiac arrest: TdP degenerating into VF causes SCA. In approximately 3–5% of LQTS patients, SCA is the first clinical manifestation. Resuscitation is successful in most cases if timely CPR/defibrillation occurs. Prior SCA is the strongest risk factor for future SCA.

Torsades de Pointes ECG features:

Back to Table of Contents

8. Treatment: Beta-Blockers and Mexiletine

Beta-blockers are first-line therapy for symptomatic congenital LQTS:

Mexiletine (sodium channel blocker) for LQTS3:

Potassium supplementation in LQTS2: Elevating serum K+ to 4.5–5.0 mEq/L augments IKr channel activity (paradoxically, higher extracellular K+ increases hERG conductance by relieving inactivation); oral K+ and/or spironolactone supplementation strategies reduce QTc and TdP burden.

Left cardiac sympathetic denervation (LCSD): Surgical removal of the left stellate ganglion and lower thoracic sympathetic chain reduces cardiac sympathetic tone. Success rate ~50–70% reduction in SCA/syncope events. Indicated as adjunct therapy when beta-blockers are maximally dosed or not tolerated, and/or ICD shocks are frequent.

Back to Table of Contents

9. ICD and High-Risk Management

Implantable cardioverter-defibrillator (ICD) indications in LQTS:

ICD considerations in LQTS:

Pacemaker (without ICD): Indicated for LQTS3 patients with significant pause-dependent TdP or symptomatic bradycardia; pacing rates of 80–90 bpm eliminate the long-pause TdP trigger.

Back to Table of Contents

10. Drug Avoidance and Lifestyle

QT-prolonging drug avoidance is one of the most important management aspects:

Electrolyte vigilance:

Activity restrictions:

Pregnancy and postpartum in LQTS2: Enhanced surveillance during postpartum; continue beta-blockers (safe in breastfeeding); avoid IKr-blocking drugs.

Back to Table of Contents

11. Research Papers

The following PubMed topic searches return current peer-reviewed literature relevant to this condition. Each link opens a live PubMed query.

Back to Table of Contents

12. Connections

Back to Table of Contents